Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (3): 519-520.doi: 10.4103/1673-5374.346486

Previous Articles     Next Articles

SARS-CoV-2 getting into the brain; neurological phenotype of COVID-19, and management by nano-biotechnology

Małgorzata Kujawska*, Ebrahim Mostafavi*, Ajeet Kaushik*   

  1. Department of Toxicology, Poznan University of Medical Sciences, Poznań, Poland (Kujawska M)
    Stanford Cardiovascular Institute/Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA (Mostafavi E)
    NanoBioTech Laboratory, Health Systems Engineering, Department of Natural Sciences, Florida Polytechnic University, Lakeland, FL, USA (Kaushik A)
  • Online:2023-03-15 Published:2022-08-26
  • Contact: Małgorzata Kujawska, PhD, kujawska@ump.edu.pl; Ebrahim Mostafavi, PhD, ebimsv@stanford.edu; Ajeet Kaushik, PhD, akaushik@floridapoly.edu.

PDF

63

Abstract: Human coronavirus infection getting into the brain: By February 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, causing the coronavirus disease 2019 (COVID-19) outbreak, has infected around 415 million people, and caused ~5.8 million deaths worldwide (WHO, https://covid19.who.int/). As SARS-CoV-2 replicates during the infection, it undergoes genetic mutation to generate variants with varying characteristics and mutation frequencies. The emerging, over time, new variants that differ with transmissibility, immunity, and infection severity pose continuous challenges to established COVID-19 management strategies and regulations. Several SARS-CoV-2 variants such as Omicron (B.1.1.529), Delta (B.1.617.2), UK (B.1.17), South Africa (B.1.351), Brazil (P.1), and New York B.1.525–B.1.526 were detected worldwide and accelerated 
severity of COVID-19 pandemic (Figure 1A; McQuaid et al., 2021).